SCHEMBL21180451

SCHEMBL21180451

CC(N)c1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 11/20 0.69
LMNA P02545 2/20 0.58
TP53 P04637 1/20 0.58
HTT P42858 1/20 0.58
HTR2A P28223 2/20 0.42
HTR2C P28335 1/20 0.42
HTR2B P41595 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
CYP3A4 P08684 1/20 0.40
NFKB1 P19838 1/20 0.40
PNMT P11086 1/20 0.40
SLC6A4 P31645 1/20 0.40
KCNH2 Q12809 1/20 0.40
MC4R P32245 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22279497 1.00 PDE2A (0.69) PDE2ALMNATP53HTTHTR2A
SCHEMBL29472446 1.00 PDE2A (0.69) PDE2ALMNATP53HTTHTR2A
SCHEMBL26620225 1.00 PDE2A (0.69) PDE2ALMNATP53HTTHTR2A
SCHEMBL14120796 0.85 PDE2A (0.54) PDE2ALMNATP53HTTHTR2A
SCHEMBL2629463 0.85 PDE2A (0.73) PDE2AHTR2ACYP1A2CYP2D6CYP2C9
SCHEMBL20072514 0.81 PDE2A (0.69) PDE2AHTR2ACYP1A2CYP2D6CYP2C9
SCHEMBL27519860 0.81 PDE2A (0.69) PDE2AHTR2ACYP1A2CYP2D6CYP2C9
SCHEMBL18075371 0.81 PDE2A (1.00) PDE2ALMNAHTR2ACYP1A2CYP2D6
SCHEMBL21180449 0.81 PDE2A (0.49) PDE2ALMNATP53HTTHTR2A
SCHEMBL29472439 0.81 PDE2A (0.49) PDE2ALMNATP53HTTHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113660983-A Carbamate derivatives and uses thereof 诺瑟拉有限公司 2021-11-16 CN disclosed
EP-3270926-B1 TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2021-08-04 EP disclosed
WO-2020152361-A1 CARBAMATE DERIVATIVES AND USES THEREOF NodThera Limited (GB) 2020-07-30 WO disclosed
US-10358435-B2 Triazolyl pyrimidinone compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2019-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10358435-B2 Triazolyl pyrimidinone compounds as PDE2 inhibitors PDE2A, PDE12, PDE4D PDE2A 1/4885LMNA 4687/4885TP53 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.